Kadimastem and itolerance successfully complete pre-ind meeting with the fda for its type 1 diabetes treatment

Companies advance collaborative clinical development of itol-102: a potential cure for diabetes without the need for chronic life-long immune suppression zurich and ness ziona, israel , feb. 25, 2025 /prnewswire/ -- nls pharmaceutics ltd. (nasdaq: nlsp) ("nls") and kadimastem ltd.

NLSP Ratings Summary

NLSP Quant Ranking